Ronald Barrett
Direttore/Membro del Consiglio presso JANUX THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Ronald W.
Barrett founded XenoPort, Inc. in 1999, where he worked as Chief Executive Officer & Director from 2001 to 2015.
Dr. Barrett also currently works at Janux Therapeutics, Inc., as Director from 2021 and Quadriga BioSciences, Inc., as Director.
Dr. Barrett also formerly worked at Medikine, Inc., as Chairman & Chief Executive Officer from 2017 to 2023, Concert Pharmaceuticals, Inc., as Independent Director from 2014 to 2022, Abbott Laboratories, as Principal in 1989, and Affymax Research Institute, as Senior Vice President-Research from 1989 to 1999.
Dr. Barrett received his undergraduate degree from Bucknell University and doctorate degree from Rutgers State University of New Jersey.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
-.--% | 15/02/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Ronald Barrett
| Società | Posizione | Inizio |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 07/09/2021 |
Quadriga BioSciences, Inc.
 Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Ronald Barrett
| Società | Posizione | Fine |
|---|---|---|
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Amministratore Delegato | 01/07/2023 |
| CONCERT PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 09/06/2022 |
| XENOPORT, INC. | Amministratore Delegato | 29/09/2015 |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Direttore Tecnico/Scientifico/R&S | 01/01/1999 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/1989 |
Formazione di Ronald Barrett
| Bucknell University | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| JANUX THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Health Technology |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Health Technology |
- Borsa valori
- Insiders
- Ronald Barrett
